Application of synthetic biology in infectious and communicable diseases
2026 (English)In: Synthetic Biology and its Consequences in Present Healthcare / [ed] Bhupendra G. Prajapati; Biswajit Basu; Anirudha Dutta; Ayan Chatterjee, Elsevier, 2026, p. 181-200Chapter in book (Other academic)
Abstract [en]
Infectious diseases have profoundly impacted human history, causing economic turmoil and societal collapse. The Ebola epidemic (2013-16) strained West Africaâs fragile healthcare systems, while the severe acute respiratory syndrome coronavirus outbreak (2002-3) disrupted trade and travel, particularly in Canada and Singapore. More recently the COVID-19 pandemic has disrupted global socioeconomic structures, driving biologists to seek innovative solutions. Since the discovery of penicillin in 1928 antibiotics have revolutionized bacterial infection treatment, significantly reducing mortality rates. However research into new antibiotics declined after the mid-1950s, despite the growing challenge of antibiotic-resistant bacteria. Later, the invention of synthetic biology in early 2000s helped to design and modifie biological parts to address biomedical challenges. This chapter reviews recent advances in living therapeutics and diagnostics, highlighting their impact on infectious diseases and associated challenges.
Place, publisher, year, edition, pages
Elsevier, 2026. p. 181-200
Keywords [en]
Bacteria, COVID-19, Diagnosis, Economic and social effects, Economics, Viruses, Communicable disease, Genetic modification tool, Genetic modifications, Healthcare systems, Infectious disease, Severe acute respiratory syndrome coronavirus, Singapore, Socio-economics, Synthetic biology, West Africa, Antibiotics
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:lnu:diva-150652DOI: 10.1016/B978-0-443-33649-2.00007-1Scopus ID: 2-s2.0-105023943910ISBN: 9780443336492 (print)ISBN: 9780443336508 (print)OAI: oai:DiVA.org:lnu-150652DiVA, id: diva2:2114976
2026-11-032026-11-032026-11-03Bibliographically approved